Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B)

Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), also known as Decoy receptor 3 (DcR3), TR6, or M68, is a secreted member of the tumor necrosis factor receptor superfamily that functions as a soluble decoy receptor. Unlike most TNFR superfamily members, which are membrane-bound, TNFRSF6B lacks a transmembrane domain and is found in soluble form in the extracellular space[1][7]. TNFRSF6B binds and neutralizes key ligands of the TNF superfamily, such as Fas ligand (FasL, TNFSF6), LIGHT (TNFSF14), and TL1A (TNFSF15), thereby blocking their interaction with death receptors on cells. This leads to inhibition of apoptosis and enables immune escape, particularly in tumor cells. TNFRSF6B is frequently overexpressed in a range of malignancies including pancreatic, gastric, colorectal, liver, lung, and esophageal cancers, and its elevated expression is associated with increased tumor progression, metastasis, and poor patient prognosis[2][4][5][8][9]. By interfering with apoptosis and modulating immune signaling pathways, TNFRSF6B contributes to tumor cell survival, chemotherapy resistance, and immune evasion. There are currently no direct therapeutic agents in clinical use targeting TNFRSF6B, but it is actively studied as both a potential therapeutic target and a biomarker for prognosis and treatment response in cancer[2][5].

Other names

Decoy receptor 3DcR3TR6M68DCR3M68EDJ583P15.1.1Decoy receptor for Fas ligand

Neutralization of TNFRSF6B decoy function (restores sensitivity to FasL/TNF-family induced apoptosis in tumor cells; studied using neutralizing antibodies or RNA interference in research settings)